Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

1.5K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.5K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the Gap: The Emerging Role of memory CD8+ T Cells in Fibrotic Interstitial Lung Disease.

American journal of respiratory cell and molecular biology·2026
Same author

Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis.

Respiratory medicine·2026
Same author

Validation of the ICO-OCEX tool for competency-based assessment in ophthalmology residency programs.

BMC medical education·2026
Same author

Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.

The European respiratory journal·2026
Same author

The Ophthalmology Surgical Competency Assessment Rubric for penetrating keratoplasty.

Indian journal of ophthalmology·2025
Same author

Incidence of New Comorbidities After Steroid Use in Patients With Sarcoidosis: An International Cross-Sectional Survey.

Chest·2025

Related Experiment Video

Updated: Mar 1, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.9K

Neuro-ophthalmic sarcoidosis.

Robert P Baughman1, Kenneth L Weiss2, Karl C Golnik3

  • 1Department of Medicine.

Eye and Brain
|May 26, 2017
PubMed
Summary

Neuro-ophthalmic sarcoidosis affects one-third of patients, commonly involving the optic nerve. Treatment includes systemic therapy, often starting with corticosteroids, with steroid-sparing agents and TNF inhibitors for chronic or refractory cases.

Keywords:
infliximabmethotrexatemultiple sclerosisoptic neuritisprednisonesarcoidosis

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K
Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

20.3K

Related Experiment Videos

Last Updated: Mar 1, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.9K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K
Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo
08:17

Optical Coherence Tomography: Imaging Mouse Retinal Ganglion Cells In Vivo

Published on: September 22, 2017

20.3K

Area of Science:

  • Ophthalmology
  • Neurology
  • Immunology

Background:

  • Neurosarcoidosis frequently impacts the visual system, with optic nerve involvement being the most common presentation.
  • Differential diagnosis is crucial, as other conditions like multiple sclerosis can mimic neuro-ophthalmic sarcoidosis.
  • Sarcoidosis diagnosis relies on identifying its multi-organ involvement and specific diagnostic tests.

Purpose of the Study:

  • To summarize the key aspects of neuro-ophthalmic sarcoidosis, including its manifestations, diagnosis, and treatment strategies.

Main Methods:

  • Review of existing literature on neuro-ophthalmic sarcoidosis.
  • Analysis of common clinical presentations and diagnostic criteria.
  • Evaluation of therapeutic approaches, including corticosteroids, cytotoxic agents, and biologic therapies.

Main Results:

  • Approximately one-third of neurosarcoidosis patients experience neuro-ophthalmic disease.
  • Optic nerve compromise is the most frequent ocular manifestation.
  • Systemic therapy is generally required, with corticosteroids as first-line treatment.

Conclusions:

  • Neuro-ophthalmic sarcoidosis necessitates systemic treatment, often involving a stepwise approach.
  • Steroid-sparing agents like methotrexate and azathioprine are valuable for managing chronic disease.
  • Tumor necrosis factor inhibitors show promise for refractory neuro-ophthalmic sarcoidosis.